Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis - 13/07/12
Abstract |
Background |
Multiple trials demonstrate the tolerability and safety of etanercept. However, there are limited data on etanercept tolerability in large populations of patients with psoriasis or with extended therapy.
Objectives |
We sought to determine whether there is an increased safety risk associated with higher etanercept doses or with extended exposure in patients with psoriasis.
Methods |
Integrated adverse event (AE) data from etanercept psoriasis trials were used to evaluate short-term (up to 12 weeks from controlled studies) and long-term (up to 144 weeks from uncontrolled extension studies) safety of etanercept (25 mg once weekly to 50 mg twice weekly). Long-term data were stratified by treatment regimens. Rates of noninfectious and infectious AE and standardized incidence ratios for malignancies were determined.
Results |
In short-term analyses, rates of noninfectious and infectious AE and serious noninfectious and infectious AE were comparable between placebo and etanercept groups. In both short- and long-term analyses, there were no dose-related increases in these events. Cumulative event rates for serious infections were not significantly different across dose groups and over time. The standardized incidence ratios for malignancies excluding nonmelanoma skin cancers did not achieve statistical significance. There was no increase in overall malignancies with etanercept therapy compared with the psoriasis population. Lymphoma (n = 2 patients), demyelination (n = 2), congestive heart failure (n = 7), and opportunistic infection (n = 1) were rare.
Limitations |
Study limitations include the rarity of some events and the resultant broad 95% confidence intervals.
Conclusions |
In this integrated analysis, etanercept was well tolerated, and there were no signs of dose-related or cumulative toxicity over time.
Le texte complet de cet article est disponible en PDF.Key words : clinical trials, etanercept, long-term treatment, psoriasis, safety
Abbreviations used : AE, BCC, BIW, CHF, CI, MI, MTX, NMSC, QW, SCC, SEER, SIR, TNF
Plan
Supported by Immunex Corp, a wholly owned subsidiary of Amgen Inc, and by Wyeth, which was acquired by Pfizer Inc in October 2009. |
|
Disclosure: Dr Pariser has been a consultant and/or advisory board member for Abbott, Galderma, and Stiefel, and he has been investigator for Abbott, Amgen, Basilea, Dow, Eli Lilly, Galderma, Johnson and Johnson Consumer Products, Leo, MELA Sciences, Novo Nordisk, Peplin, Pfizer, Photocure, Shionogi, and Stiefel. Dr Leonardi has been a consultant for Abbott, Amgen, Centocor, and Pfizer; been an investigator for Abbott, Amgen, Celgene, Centocor, Genentech, Eli Lilly, Genzyme, Pfizer, Incyte, Schering-Plough, Novartis, Novo Nordisk, Vascular Biogenics, and Wyeth (Wyeth was acquired by Pfizer in October 2009); and served as a speaker for Abbott, Amgen, and Centocor. Dr Gordon has been a consultant and/or advisory board member for Abbott, Amgen, Celgene, Centocor, Lilly, Merck, and Medicis, and he has been an investigator for Amgen, Abbott, Centocor, and Celgene. Dr Gottlieb is a consultant and/or advisory board member for Abbott, Actelion, Alnylam, Amgen, Astellas, Beiersdorf, BIND Biosciences, Bristol Myers Squibb, Canfite, Centocor, Celgene, Cytokine Pharmasciences, Dermipsor, Immune Control, Incyte, Magen Biosciences, Merck, Novo Nordisk, Ono, Pfizer, PureTech, Schering, TEVA, and UCB, and has been a recipient of research/educational grants paid to Tufts Medical Center by Abbott, Amgen, Celgene, Centocor, Immune Control, Novartis, Novo Nordisk, Pfizer, and UCB. Dr Tyring has been an investigator and speaker for Amgen. Dr Papp has been a consultant, advisory board member, and investigator for Abbott, Amgen, Celgene, Centocor, Janssen Ortho, MedImmune, Pfizer, Schering-Plough, and Wyeth (Wyeth was acquired by Pfizer in October 2009), and has served as a speaker for Amgen, Abbott, Celgene, Janssen Ortho, Pfizer, Schering-Plough, and Wyeth (Wyeth was acquired by Pfizer in October 2009). Drs Li and Baumgartner are employees and stock holders of Amgen. |
Vol 67 - N° 2
P. 245-256 - août 2012 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?